Hamza Suria, AnaptysBio CEO
The biotech behind GlaxoSmithKline's PD-1 just scored a $250M cash deal for royalties
With Merck and Bristol Myers Squibb still dominating the PD-(L)1 space and the threat of lower-cost options coming from behind, is there still room for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
